| Anti-viral / P3 Facility Programs |
|
|
|
With the designated BSL-2 and BSL-3 labs,
First Flight Biosciences provides services for drug discovery for HIV, HCV and flaviviruses such as Dengue virus, West Nile virus, Encephalitis viruses which cause serious diseases in numerous regions. First Flight Biosciences specializes in anti-viral assay development with different formats in high trough-put screening.
|
|
|
|
Anti-HIV-1 assay development:
|
|
|
| A cell-based 384-well format anti-HIV-1 screening assay using infectious HIV-1 system has been established by First Flight Biosciences. This assay is used to identify anti-HIV-1 compounds targeting at any stage of the HIV-1 replication and provides the opportunity to discover new classes of anti-HIV-1 drugs. In parallel, cytotoxicity assay is incorporated in the service to evaluate the toxicity of test compounds. |
|
|
|
|
|
Dose response curve obtained from First Flight Biosciences anti-HIV-1 compound screening assay
|
|
|
|
Our service includes:
|
|
1.
|
Evaluation of effect of drug combination against HIV;
|
|
2.
|
Generation of drug-resistant HIV-1 by in vitro virus passage;
|
|
3.
|
Genotyping and phenotyping for viruses derived from HIV-infected patients or drug-resistant virus generated for study purpose;
|
|
|
|
4.
|
In vitro biochemical assay development for HIV integrase.
|
|
5.
|
CCR5 compound screening |
|
|
|
|
|
Anti-HIV-1 compounds screening service provides:
|
|
|
 |
384-well format, cell-based infectious HIV-1 system; |
|
Single dose screening: >10,000 compounds per month; |
|
IC50 determination: >1000 compounds per month; |
|
Lead compound screening against the HIV-1 strain panel; |
|
Lead compound screening against the cell line panel; |
|
Lead compound screening against Peripheral Blood Mononuclear Cell (PBMC); |
|
The data include both antivirus and cytotoxicity assay. |
|
|
|
 |
|
A First Flight Biosciences scientist working in the Biosafety Level-3 (BSL-3) laboratory
|
|
|
Anti-HCV assay development and compound screening:
|
|
|
|
A 96-well format transient HCV replicon screening assay based on HCV-1b system has been established in First Flight Biosciences. It can be modified to fit our client’s need for other HCV strain, such as 1a.
|
|
|
|
Our service includes:
|
|
1.
|
Evaluation of Effect of drug combination against HCV;
|
|
2.
|
Entry studies of inhibitors using pseudovirus infection system;
|
|
3.
|
Generation of mutated HCV replicons by site-directed mutagenesis;
|
|
4.
|
Genotyping and phenotyping for viruses derived from HCV-infected patients or drug-resistant virus generated for study purpose;
|
|
|
|
5.
|
RNA polymerase assay development which is used to determined the compound activity against HCV NS5b polymerase. The validated assay is HTS compatible;
|
|
|
|
6.
|
Assay development for mechanism of action of lead compounds.
|
|
|
|
|
Anti-Dengue viruses assay development and compound screening
|
|
|
|
An established 96-well immunoassay is available for determining the compound activity against Dengue virus1, 2, 3, or 4. Meanwhile, the cytotoxicity evaluation of the tested compounds is also provided within our service.
|
|
|
|
We also provides:
|
|
1.
|
Compound profiling against different serotypes and other flaviviruses;
|
|
2.
|
RNA polymerase assay development which is used to determined the compound activity against Dengue virus polymerase. The validated assay is HTS compatible;
|
|
|
|
3.
|
Assay development for mechanism of action of lead compounds.
|
|
|
|
Anti-West Nile viruses assay development and compound screening
|
|
|
|
An established 96-well assay is available in HDB for determining the compound inhibition of West Nile virus-induced cytopathic effect (CPE). Evaluation of the tested compound cytotoxicity is included in the service in parallel.
|
|
|
|
We also provides:
|
|
1.
|
Compound profiling against other flaviviruses;
|
|
2.
|
RNA polymerase assay development which is used to determined the compound activity against West Nile virus polymerase. The validated assay is HTS compatible;
|
|
|
|
3.
|
Assay development for mechanism of action of lead compounds.
|
|
|
|
|
Anti-Japanese B encephalitis viruses assay development and compound screening
|
|
|
|
An established 96-well assay is available in First Flight Biosciences for determining the compound inhibition of Japanese B encephalitis virus-induced cytopathic effect (CPE). Evaluation of the tested compound cytotoxicity is also included in the service in parallel.
|
|
|
|
We also provides:
|
|
1.
|
Compound profiling against other flaviviruses;
|
|
2.
|
RNA polymerase assay development which is used to determined the compound activity against Japanese B encephalitis virus polymerase. The validated assay is HTS compatible;
|
|
|
|
3.
|
Assay development for mechanism of action of lead compounds.
|
|
|
|
|
Anti-bacteria Programs
|
|
|
|
First Flight Biosciences provides services for anti-bacterial drug discovery. Guided by Clinical and Laboratory Standards Institute (CLSI), First Flight Biosciences has established minimal inhibition concentration (MIC) assay with more than a dozen of ATCC quality control bacterial strains. With a dedicated team and sophisticated facility, First Flight Biosciences is capable of screening and validating drug-resistant strains, as well as acquiring clinical isolates from local hospitals which are among many of First Flight Biosciences’s strategic collaborators.
|
|
|
|
First Flight Biosciences provides, but not limited to, the following anti-bacterial services
|
|
1.
|
Standard MIC assay for anti-bacterial compound screening;
|
|
2.
|
Gel-based mechanism of action studies, including gyrase assay and topoisomerase assays;
|
|
3.
|
Generation and characterization of drug-resistant bacterial strain;
|
|
4.
|
Compound profiling against clinical isolates.
|
|
